Androgens repress expression of the f-box protein Skp2 via p107 dependent and independent mechanisms in LNCaP prostate cancer cells

Prostate

Volumn 72, Issue 2, 2012, Pages 225-232

  Jiang, Jingting ^a,b   Pan, Yunqian ^c,d   Regan, Kevin M ^e   Wu, Changping ^a   Zhang, Xueguang ^b   Tindall, Donald J ^e   Huang, Haojie ^c,d  

^a SOOCHOW UNIVERSITY   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^e MAYO CLINIC   (United States)

Author keywords

androgen; p107; Skp2

Indexed keywords

ANDROGEN; CYCLOHEXIMIDE; DACTINOMYCIN; F BOX PROTEIN; MESSENGER RNA; PROTEIN P107; S PHASE KINASE ASSOCIATED PROTEIN 2;

ARTICLE; CANCER CELL; CELL CYCLE; CELL STRAIN LNCAP; CONTROLLED STUDY; ELECTROPORATION; ENZYME REPRESSION; FLUORESCENCE ACTIVATED CELL SORTING; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; NORTHERN BLOTTING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; WESTERN BLOTTING;

BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; HUMANS; MALE; METRIBOLONE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RETINOBLASTOMA-LIKE PROTEIN P107; S-PHASE KINASE-ASSOCIATED PROTEINS; TESTOSTERONE CONGENERS;

EID: 84455161127     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21430     Document Type: Article

References (29)

1. Isaacs JT,. Antagonistic effect of androgen on prostatic cell death. Prostate 1984; 5: 545-557. (Pubitemid 14016047)
2. Kyprianou N, Isaacs JT,. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 1988; 122: 552-562. (Pubitemid 18060946)
3. Huang H, Zegarra-Moro OL, Benson D, Tindall DJ,. Androgens repress Bcl-2 expression via activation of the retinoblastoma (RB) protein in prostate cancer cells. Oncogene 2004; 23: 2161-2176. (Pubitemid 38482531)
4. Scher HI, Sawyers CL,. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23: 8253-8261. (Pubitemid 46211563)
5. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML,. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52: 6940-6944. (Pubitemid 23006303)
6. Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW, Scher HI,. Prostate cancer cell cycle regulators: Response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst 1999; 91: 1869-1876.
7. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM,. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624-629.
8. Bohrer LR, Chen S, Hallstrom TC, Huang H,. Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: A potential mechanism of androgen-refractory progression of prostate cancer. Endocrinology 2010; 151: 5136-5145.
9. Chen S, Bohrer LR, Rai AN, Pan Y, Gan L, Zhou X, Bagchi A, Simon JA, Huang H,. Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat Cell Biol 2010; 12: 1108-1114.
10. Verras M, Lee J, Xue H, Li TH, Wang Y, Sun Z,. The androgen receptor negatively regulates the expression of c-Met: Implications for a novel mechanism of prostate cancer progression. Cancer Res 2007; 67: 967-975.
11. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP,. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66: 2815-2825.
12. Zhang H, Kobayashi R, Galaktionov K, Beach D,. p19Skp1 and p45Skp2 are essential elements of the cyclin A-CDK2 S phase kinase. Cell 1995; 82: 915-925.
13. Carrano AC, Eytan E, Hershko A, Pagano M,. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999; 1: 193-199. (Pubitemid 129500937)
14. Tedesco D, Lukas J, Reed SI,. The pRb-related protein p130 is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCF(Skp2). Genes Dev 2002; 16: 2946-2957. (Pubitemid 35334742)
15. Kamura T, Hara T, Kotoshiba S, Yada M, Ishida N, Imaki H, Hatakeyama S, Nakayama K, Nakayama KI,. Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation. Proc Natl Acad Sci USA 2003; 100: 10231-10236. (Pubitemid 37071861)
16. Huang H, Regan KM, Wang F, Wang D, Smith DI, van Deursen JM, Tindall DJ,. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci USA 2005; 102: 1649-1654. (Pubitemid 40209222)
17. Yang G, Ayala G, De Marzo A, Tian W, Frolov A, Wheeler TM, Thompson TC, Harper JW,. Elevated Skp2 protein expression in human prostate cancer: Association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 2002; 8: 3419-3426. (Pubitemid 35340716)
18. Ben-Izhak O, Lahav-Baratz S, Meretyk S, Ben-Eliezer S, Sabo E, Dirnfeld M, Cohen S, Ciechanover A,. Inverse relationship between Skp2 ubiquitin ligase and the cyclin dependent kinase inhibitor p27Kip1 in prostate cancer. J Urol 2003; 170: 241-245. (Pubitemid 36734470)
19. Shim EH, Johnson L, Noh HL, Kim YJ, Sun H, Zeiss C, Zhang H,. Expression of the F-box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate. Cancer Res 2003; 63: 1583-1588. (Pubitemid 36373647)
20. Lin HK, Chen Z, Wang G, Nardella C, Lee SW, Chan CH, Yang WL, Wang J, Egia A, Nakayama KI, Cordon-Cardo C, Teruya-Feldstein J, Pandolfi PP,. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 2010; 464: 374-379.
21. Lu L, Schulz H, Wolf DA,. The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells. BMC Cell Biol 2002; 3: 22.
22. Liu SL, Rand A, Kelm RJ Jr, Getz MJ,. The retinoblastoma gene family members pRB and p107 coactivate the AP-1-dependent mouse tissue factor promoter in fibroblasts. Oncogene 2000; 19: 3352-3362. (Pubitemid 30479330)
23. Huang H, Cheville JC, Pan Y, Roche PC, Schmidt LJ, Tindall DJ,. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J Biol Chem 2001; 276: 38830-38836.
24. Wang H, Sun D, Ji P, Mohler J, Zhu L,. An AR-Skp2 pathway for proliferation of androgen-dependent prostate-cancer cells. J Cell Sci 2008; 121: 2578-2587.
25. Zhang L, Wang C,. F-box protein Skp2: A novel transcriptional target of E2F. Oncogene 2006; 25: 2615-2627.
26. Mohler JL, Gregory CW, Ford OH 3rd, Kim D, Weaver CM, Petrusz P, Wilson EM, French FS,. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10: 440-448. (Pubitemid 38173980)
27. Lu S, Liu M, Epner DE, Tsai SY, Tsai MJ,. Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol Endocrinol 1999; 13: 376-384. (Pubitemid 29113870)
28. Tsihlias J, Zhang W, Bhattacharya N, Flanagan M, Klotz L, Slingerland J,. Involvement of p27Kip1 in G1 arrest by high dose 5 alpha-dihydrotestosterone in LNCaP human prostate cancer cells. Oncogene 2000; 19: 670-679. (Pubitemid 30102918)
29. Knudsen KE, Arden KC, Cavenee WK,. Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J Biol Chem 1998; 273: 20213-20222. (Pubitemid 28377582)